{
  "report_rows": [
    {
      "kpi": "Adjusted EPS (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$1.90 vs. cons $1.84",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Biotechnology/bioprocessing core growth & equipment orders (Q2)",
      "prediction": "BEAT",
      "answer": "pred ~+7% core, equipment orders +20-30% y/y vs. cons ~+6% / +MSD",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Core (organic) revenue growth (Q2 2026)",
      "prediction": "IN-LINE",
      "answer": "pred ~2.5% vs. cons ~2%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 adjusted EPS guidance",
      "prediction": "BETTER",
      "answer": "guide ~$8.45-8.60 (mid ~$8.53) vs. cons ~$8.50 (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY2026 core revenue growth range",
      "prediction": "UNCHANGED",
      "answer": "guide 3%-6% (anchored low end ~3.5%) vs. cons ~3.5% (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "Exit-Q4 / 2H mid-single-digit core acceleration credibility",
      "prediction": "UNKNOWN",
      "answer": "guide exit-Q4 ~+MSD (~5%) vs. cons ~4-5% (2H/Q4 2026)",
      "confidence": "LOW"
    },
    {
      "kpi": "Q3 2026 core growth guide",
      "prediction": "UNCHANGED",
      "answer": "guide ~+low-to-mid single digits (~3%) vs. cons ~3% (Q3 2026)",
      "confidence": "LOW"
    },
    {
      "kpi": "Masimo deal timing/financing & interest expense",
      "prediction": "UNKNOWN",
      "answer": "guide close later-2026, net debt ~2.5x EBITDA vs. cons excludes deal (FY2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 2.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 1.0,
  "day5_path": "FADE",
  "day5_rationale": "Expect a clean Q2 beat (DHR's typical pattern) plus a modest EPS guide bump and a second quarter of >20-30% bioprocessing equipment orders to drive an initial +2-3% idiosyncratic pop. But the stock has already rallied ~15% off May lows into the print on improved lab-tool sentiment (Agilent/ICON/Bio-Techne), so much of the good news is priced. The 2H re-acceleration remains a 'show-me' math story (headwinds fading rather than end-markets improving), so out-period FY/2027 estimates barely rise even after the beat; skepticism on the exit-Q4 mid-single-digit ramp plus Masimo capital-deployment overhang causes the pop to partially give back over the week.",
  "day5_confidence": "LOW"
}